Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.[1]
Clinical data | |
---|---|
Trade names | Perfan |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 50% (oral) |
Protein binding | 85% |
Metabolism | Liver (oxidation) |
Elimination half-life | 4 to 10 hours |
Excretion | Renal (60 to 70%) |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C12H12N2O2S |
Molar mass | 248.30 g·mol−1 |
3D model (JSmol) |
|
Melting point | 255 to 258 °C (491 to 496 °F) (decomposes) |
| |
| |
(verify) |